海正药业去年营收97.87亿元，英夫马芬净、奥利司他等产品收入增加明显

Business Performance by Sector - The pharmaceutical manufacturing sector reported revenue of approximately 6.05 billion, with a gross margin of 60.35% [1] - The pharmaceutical commercial sector generated revenue of about 3.51 billion, but experienced a significant decline in gross margin to 19.41% [1] - The CMO/CDMO/CRO business had revenue of approximately 7.96 million, with a gross margin of 58.73%, but saw a drastic decrease in performance [1] - Other business segments reported revenue of around 8.93 million, with a gross margin of 48.11% [1] - Overall, the subtotal for all sectors was approximately 9.57 billion in revenue, with a gross margin of 45.33% [1] Strategic Initiatives - The company successfully transitioned from a general agent to a provincial agent, exceeding annual targets and reshaping its business structure [2] - The pharmaceutical e-commerce business achieved significant growth through targeted marketing and expansion into lower-tier markets, with key products showing substantial year-on-year increases [2] - The export formulation business launched three new products in the U.S., achieving profitability in the first year and signing exclusive agreements with three major pharmaceutical companies [2] - The company strengthened its relationships with major clients in the pharmaceutical raw materials sector, leading to stable revenue growth [2] Animal Health Business - The company optimized its sales strategy for economic animal health products, enhancing collaboration with group clients and increasing control over end customers [3] - The integration of the pig health drug and vaccine teams has led to the promotion of a comprehensive "prevention + treatment" solution [3] - The company successfully launched four major new drugs and five new veterinary drugs during the reporting period, with a strong pipeline in domestic markets [3] - The company is actively expanding into international markets, with five international registration submissions completed [3]